Appendix 1—table 16. Routine coverage values used for the counterfactual comparative (business-as-usual) scenario, following the assumptions in Appendix 1—table 14.
Target population taken from United Nations World Population Prospects (UNWPP) 2019 revision. Countries: Burkina Faso (BFA), Bangladesh (BGD), Democratic Republic of the Congo (COD), Ethiopia (ETH), Ghana (GHA), Kenya (KEN), Niger (NER), Nigeria (NGA), South Sudan (SSD), Chad (TCD). Vaccines: 1st dose measles vaccine (MCV1), 2nd dose measles vaccine (MCV2), yellow fever vaccine (YF), meningococcal A vaccine (MenA).
| Country | Vaccine | Year | Age from | Age to | Coverage (national level) |
|---|---|---|---|---|---|
| BFA | MenA | 2020–2030 | 0 | 0 | 85% |
| BGD | MCV1 | 2020–2030 | 0 | 0 | 97% |
| MCV2 | 2020–2030 | 2 | 2 | 93% | |
| COD | YF | 2020–2030 | 0 | 0 | 74% |
| ETH | MCV1 | 2020–2030 | 0 | 0 | 64% |
| MCV2 | 2020–2030 | 2 | 2 | 31% | |
| GHA | YF | 2020–2030 | 0 | 0 | 89% |
| KEN | MCV1 | 2020–2030 | 0 | 0 | 92% |
| MCV2 | 2020–2030 | 2 | 2 | 45% | |
| NER | MenA | 2020–2030 | 0 | 0 | 96% |
| NGA | MCV1 | 2020–2030 | 0 | 0 | 61% |
| MCV2 | 2020–2030 | 2 | 2 | 19% | |
| MenA | 2020–2030 | 0 | 0 | 61% | |
| YF | 2020–2030 | 0 | 0 | 60% | |
| SSD | MCV1 | 2020–2030 | 0 | 0 | 51% |
| TCD | MCV1 | 2020–2030 | 0 | 0 | 39% |
| TCD | MenA | 2020–2030 | 0 | 0 | 70% |